Perrigo Counts 32 Billion Reasons To Reject Mylan Offers
This article was originally published in The Tan Sheet
Executive Summary
In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.
You may also be interested in...
Pfizer Notches “Milestone” In OTC Switch Plan
Nexium 24HR’s is “the first significant milestone” Pfizer’s Rx-to-OTC strategy, says Albert Bourla, head of the division that includes consumer products. The next milestone could be a new drug application for an OTC version of Lipitor.
Merck’s Oxytrol Could Be OTC Trailblazer For Chronic Conditions
Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.